Eloxx Pharmaceuticals, Inc. annual report, FY2013

Filing identity and reporting period

Important metadata discrepancy: The supplied filing is Senesco Technologies, Inc.’s Form 10-K for the fiscal year ended June 30, 2013, filed September 11, 2013. It is not an Eloxx Pharmaceuticals filing or a 2012 fourth-quarter report.

Business context

Senesco was a development-stage biotechnology company focused on Factor 5A/DHS gene technology for human therapeutics and agricultural applications. Its lead candidate, SNS01-T, was in a Phase 1b/2a dose-escalation study for multiple myeloma and other B-cell cancers. The company also reported nine active agricultural license agreements. It had no commercialized products and relied on external financing and development partners.

Financial performance and position

Gross margin and operating margins are not meaningful because FY2013 revenue was zero. At June 30, 2013, total assets were $7.098 million, total liabilities were $3.312 million, and stockholders’ equity was $3.786 million. The current line-of-credit balance was $2.187 million; the filing reports a 5.75% rate at year-end (broker rate of 3.75% plus 2%).

Material changes and unusual items

• Operating expenses declined 17.1%, mainly from lower research and development spending and lower patent write-offs. Research and development expense fell 18.7% to $2.087 million; 97% was allocated to human therapeutics.
• Despite lower operating expenses, net loss increased year over year, including a $1.725 million loss on settlement of warrant liabilities. A $372,000 noncash gain from the change in warrant fair value partly offset expenses.
• Financing provided $4.033 million of cash, including a January 2013 offering of common stock and warrants for $3.0 million gross and a May 2013 common-stock offering for $1.255 million gross. The company also issued 353,895 shares through its ATM for $101,000 gross; it could no longer use that facility after its November 2012 NYSE MKT delisting.
• Common shares outstanding rose from 94.1 million to 227.2 million during the fiscal year. At year-end, potentially dilutive preferred shares, warrants and options represented approximately 78.2 million additional shares, subject to their terms.

Outlook, risks and contingencies

Management estimated that available cash would fund operations only through November 2013 and stated that additional capital was needed to fund operations through at least June 30, 2014. The auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Management said it planned to seek equity or debt financing; failure to obtain funds could force it to reduce or stop research, seek partners or a sale, or cease operations.

The first two SNS01-T study cohorts were completed; the third was enrolling and treating patients. The company reported that the candidate was safe and well tolerated in those cohorts and that 2 of 6 evaluable patients met stable-disease criteria. Management estimated trial completion in the first half of 2014. These were early-stage findings, not evidence of established efficacy. The filing also cites clinical enrollment, regulatory, manufacturing-supply, intellectual-property, competition and dilution risks.

Investor verification priorities

• Confirm the issuer and period: this source is Senesco Technologies’ FY2013 10-K, not Eloxx Pharmaceuticals’ 2012 Q4 filing.
• Verify current cash runway, subsequent financing, and whether the company obtained funding after the stated November 2013 estimate.
• Review the line-of-credit demand and collateral terms, and assess whether reported working capital adequately reflects near-term obligations.
• Check subsequent SNS01-T trial enrollment, safety and efficacy results, and whether the stated completion timetable was met.
• Reconcile share counts, preferred-stock conversion terms, warrants and other potential dilution against subsequent filings.